Xilio Therapeutics Inc (XLO) - Narx-foyda koeffitsiyenti

Xilio (XLO) korporativ emblemasi va logotipi

Xilio Therapeutics, Inc. (XLO) maxsus sitokinlarni yaratish orqali daromad keltiradi, bunda xavfsiz immuno-onkologik agentlarning bozorga chiqarilishi asosiy o'sish drayveri bo'lib xizmat qiladi. Biroq, moliyaviy barqarorlik Gilead tomonidan amalga oshiriladigan to'lovlarga bog'liq, tadqiqot va ishlanmalar (R&D) xarajatlari esa zararlarga olib kelmoqda; joriy ko'rsatkich -4.40 miqdorida. Aksiyalar narxi tarixi aktivning narx harakatlarini aks ettiradi. Xilio Therapeutics, Inc. (XLO) neoplazmalar ichidagi molekulalarni faollashtirish orqali nojo'ya ta'sirlarni minimallashtirib, og'ir patologiyalar uchun terapiya imkoniyatlarini kengaytirmoqda.

xiliotx.com (XLO): Narxning foydaga nisbati 04.07.2022dan 17.11.2026gacha

Xilio Therapeutics (XLO) kompaniyasining tahliliy kesimlari

Kompaniyaning jamlanma tahlili:Xilio Therapeutics, Inc.
xiliotx.com original mahsuloti

Xilio Therapeutics, Inc. (XLO) dori vositalari uchun ixtisoslashtirilgan sovuq zanjir logistikasi xarajatlari marjalarga bevosita ta'sir ko'rsatadigan yuqori texnologiyali sektorda raqobatlashmoqda. Kompaniyaning P/E koeffitsiyenti tarixini tahlil qilish orqali investor bozor qiymatining sof foydaga nisbati orqali kapitalning qoplanish muddatini aniqlaydi, bu esa aktivlarning haddan tashqari qimmat baholanganini yoki sanoatdagi tengdoshlariga nisbatan fundamental past baholanganini aniqlash imkonini beradi.

Raqobatdosh kompaniyalar tahlili

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis Corp (PSNL) - Narxning foydaga nisbati|Erasca Corp - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath Systems Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Y-mAbs Therapeutics, Inc. YMAB|P/E multiplikatori AURA|Narx-foyda koeffitsiyenti Candel Therapeutics, Inc. CADL|P/E multiplikatori ARAY (Accuray, Inc.)|SELLAS Life Sciences - Narxning foydaga nisbati|ACTU: Narx-foyda koeffitsiyenti|Citius Oncology, Inc. - Bozor narxining sof foydaga nisbati|HURA (TuHURA Biosciences) - Narx-foyda koeffitsiyenti|TARA: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti FATE|WHWK: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TCRX (TScan Therapeutics Inc)|Biznesning o‘zini qoplash muddati Champions Oncology Inc|P/E multiplikatori XBIT (XBiotech Inc.)|Kompaniya qiymatining sof foydaga nisbati CVM|OS Therapies Inc. - P/E multiplikatori|RADX - P/E multiplikatori|ARTV: P/E multiplikatori|ANL: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti VERU|TPST: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Enochian BioSciences (RENB)|Narxning foydaga nisbati MURA (Mural Oncology PLC)|Narxning foydaga nisbati Kairos Pharma Ltd KAPA|P/E multiplikatori OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV